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Recent studies have shown the presence of troponin molecules in urine, with kidneys considered the main organs of elimina-
tion. Availability of the new generation of high-sensitivity assays has enabled detection of low concentrations of circulating 
cardiac troponins, but the high-sensitivity troponin assays are not designed for analysis of urine specimens. The aim of this 
study was to establish preliminary reference intervals for the high-sensitivity cardiac troponin I (hs-cTnI) concentrations in 
urine of healthy adults in Croatia. A total of 60 reference persons were selected (30 males and 30 females) and the concen-
trations of hs-cTnI in random urine samples were determined on the Abbott Architect i1000SR (Abbott Laboratories) ana-
lytical system with chemiluminescent immunochemical method on microparticles (CMIA, ARCHITECT STAT High Sensitive 
Troponin-I), accredited according to the HR EN ISO 15189:2012 standard (Medical laboratorieds – requirements for quality 
and competence. Geneva, International Organization for Standardization, 2012). We determined the limit of detection, total 
laboratory precision, expanded measurement uncertainty and preliminary estimates of the gender-speciﬁ c 99th percentile of 
the upper reference limit (URL) using nonparametric analysis (methods). The male and female 99th percentile cut-off values 
were 39.3 and 35.2 pg/mL, respectively. The results of this pilot study suggest that troponin I is removed from the blood by 
the kidneys and can be determined in the urine with CMIA, ARCHITECT STAT High Sensitive Troponin-I assays. Further re-
search is focused on detailed studies of biochemistry and determination of troponin I in the urine as a new biological marker.
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INTRODUCTION
Troponin is a protein molecule that makes the tro-
ponin complex. Th e troponin complex is made up of 
three types of troponin: troponin I, troponin T and 
troponin C. Troponin T is part of the troponin com-
plex linked to tropomyosin, troponin I is an ATP-ase 
activity inhibitor and prevents ATP consumption, 
while troponin C is part of the complex to which cal-
cium (Ca2+) is attached (1). Troponin I has a molecu-
lar weight of about 22.5 kDa (2). Th ere are numerous 
conditions that can increase troponin (myocardial in-
farction, pulmonary embolism, cardiac damage), but 
they all are commonly associated with cardiovascular 
damage (cardiomyocyte necrosis) (3). Troponin grows 
2-3 hours aft er heart failure, reaching maximal value 
approximately 24 hours of the damage and remaining 
elevated for up to 8 days (4).
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Within heart cells, daily exchanges of old proteins with 
new ones, including troponin, occur. Th ere is also a 
natural daily loss of cardiac cells. Th ese facts are one 
of the reasons why troponin molecules are present in 
the blood of healthy population. Th ese concentrations 
are not large and range around 0.1-0.2 ng/L (5). While 
the synthesis and presence of troponin molecules in 
the blood is well known today, the method of secre-
tion from the blood is still relatively unknown. Several 
research papers have recently tried to explain how it 
is removed from the blood. Some data indicate that 
troponin is removed in the reticuloendothelial system 
where it is cleaved into smaller fragments (5). Th ere 
are also studies showing that enzymes such as caspases 
and calpain cleave the troponin molecule into small 
fragments that are then removed from the circulation 
(4). In the literature, so far there are only two state-
ments about the presence of troponin in the urine 
(7,8). Th e fi rst one shows that it is possible to prove 
troponin T and troponin I, while the second one is a 
summary dealing only with troponin I (7,8). 
Th e hypothesis of this pilot study was that troponin 
detection in urine would be more appropriate for tro-
ponin I because it breaks in blood into smaller mole-
cules and the likelihood of detection of these smaller 
immunoreactive particles is higher than for troponin 
T (9). 
Th e primary purpose of this study was to confi rm the 
presence of troponin I molecule in urine. Th e sec-
ondary aim was to establish preliminary reference 
intervals for the highly sensitive cardiac troponin I 
(hs-cTnI) concentrations in (fi rst morning or random-
ly collected) urine of healthy adults in Croatia and to 
assess its potential as a new biological marker.
PATIENTS AND METHODS 
Th e reference interval of hs-cTnI in urine was deter-
mined in the Department of Medical Biochemistry 
and Laboratory Medicine, Merkur University Hos-
pital, Zagreb, Reference Center of the Ministry of 
Health of the Republic of Croatia for the production 
of reference values in the fi eld of general medical bio-
chemistry on a preliminary sample of 60 healthy sub-
jects (30 men and 30 women). Th e reference persons 
were selected using the following criteria: non-smoker 
aged 25-65, body weight index <30 kg/m2, absence of 
acute and chronic diseases (heart disease and thyroid 
disease, hypertension, hyperlipidemia), and avoiding 
more severe physical activity for the last 7 days and 
night work during the last 30 days. All participants 
signed their informed consent for participation in the 
research. 
Th e concentrations of hs-cTnI in random urine sam-
ples were determined on the Abbott Architect i1000SR 
(Abbott Laboratories) analytical system with chemi-
luminescent immunochemical method on micro-
particles (CMIA, ARCHITECT STAT High Sensitive 
Troponin-I), accredited according to the HR EN ISO 
15189:2012 norm (10). According to the manufactur-
er’s insert, this assay uses a sample volume of 160 μL. 
In the fi rst step, cTnI present in the sample binds to 
the specifi c mouse monoclonal anti-cTnI (capture) 
antibody coated microparticles, the epitope binding 
specifi city of which is directed against amino acids 24-
40 on the TnI protein. In the second step, a specifi c 
mouse-human chimeric, monoclonal anti-troponin I 
acridinium-labeled antibody acts as a detection anti-
body. Th is chimeric antibody, which has an epitope 
binding specifi city directed against amino acids 41-49 
on the cTnI molecule, was designed to minimize the 
susceptibility to interferences by heterophilic antibod-
ies (11). Th e method is traceable to NIST SRM 2921 
and is linear in the range of 1.2 ng/L (detection limit) 
to 50,000 ng/L. Th e limit of quantifi cation (LoQ) de-
clared by the manufacturer is 10.0 ng/L, but there is a 
possible range of quantifi cation limit of 4.0-10.0 ng/L, 
depending on the combination of Lot reagents and se-
ries of analyzers. 
Th e LoQ was determined according to the CLSI 
EP17-A2 (11), precision was assessed based on CLSI 
EP15-A2 guidelines (12), and linearity was confi rmed 
by the multicalibration curve. Expanded measure-
ment uncertainty was estimated based on the calcu-
lated within-laboratory precision and measurement 
uncertainty of calibrators. Th e 99th pe rcentile up-
per reference limit of the interval was calculated by 
nonparametric statistical analysis, according to the 
CLSI C28-A3 guidelines (13), using the MedCalc ver. 
10.0.2.0 statistical program. 
RESULTS 
Total laboratory precision was calculated according 
to the CLSI EP15-A2 guidelines (12) and was 2.23% 
(coeffi  cient of variation, CV) in the normal range and 
1.45% (CV) in the pathological area. Th e linearity of 
the methods in the declared area is confi rmed by the 
multicalibration curve. Th e LoD is the lowest detect-
able cardiac troponin concentration reliably distin-
guished from the highest cardiac troponin concentra-
tion expected to be found when replicates of a sample 
containing the zero calibrator for a cardiac troponin 
assay are tested in a sample containing a low cardiac 
troponin concentration that can confi dently be report-
ed for clinical use. Th e quantifi cation limit was deter-
mined according to the CLSI EP17-A2 guidelines (11) 
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and with the precision criteria for the highly sensitive 
test (CV <10%) (2). LoQ was verifi ed at the concentra-
tion of 4.71 ng/L with CV% 8.41% (15). Th e e xpanded 
measurement uncertainty (k=2) is calculated from the 
total laboratory precision and calibration uncertainty 
and is ±4.5% for the normal range and ±2.9% for the 
pathological area. 
Demographic characteristics and hs-cTnI concen-
trations in random urine samples of the 60 reference 
persons (30 males and 30 females) are shown in Ta-
ble 1. Th e hs-cTnI concentration was detectable in 59 
(98.3%) and quantifi ed in 51 (85.0%) random urine 
samples from the selected reference population, rang-
ing from 0.3 to 39.3 ng/L. Th e measured values of TnI 
in urine were above the detection limit (1.2 ng/L) in 
59 (98.3%) subjects and above the quantifi cation limit 
(4.7 ng/L) in 51 (85.0%) subjects. 
Th e 99th percentile of the upper limit of the reference 
interval was calculated by nonparametric statistical 
analysis, in accordance with the CLSI C28-A3 guide-
lines (13), using the MedCalc ver. 10.0.2.0 statistical 
program (Table 2). Th e 99th percentile of the upper 
limit of the reference interval was 39.3 ng/L for males 
and 35.2 ng/L for females.
Table 1. 
Demographic characteristics and hs-cTnI concentrations in 















1 Female 25 153 50 21.4 14.4
2 Female 31 158 50 20 19.3
3 Female 39 168 54 19.1 8.0
4 Female 25 164 50 18.6 29.7
5 Female 25 166 58.5 21.2 15.9
6 Female 57 160 53 20.7 5.1
7 Female 38 164 75 27.9 20.6
8 Female 57 165 69 25.3 28.7
9 Female 44 161 62 23.9 18.9
10 Female 48 170 65 22.5 0.3
11 Female 62 165 67 24.6 15.7
12 Female 51 170 70 24.2 19.7
13 Female 30 170 68 23.5 20.8
14 Female 44 165 80 29.4 20.5
15 Female 56 175 70 22.9 6.7
16 Female 59 175 86 28.1 3.3
17 Female 49 170 60 20 20.5
18 Female 47 171 73 25 16.8
19 Female 28 170 63 21.8 7.3
20 Female 29 181 63 19.2 15.6
21 Female 27 182 65 19.6 7.3
22 Female 51 164 66 24.5 27.3
23 Female 63 164 70 26 35.2
24 Female 63 164 69 25.7 19.1
25 Female 58 169 66 23.1 30.9
26 Female 35 172 54 18.3 27.2
27 Female 42 176 78 25.2 29.9
28 Female 27 168 58 20.5 26.2
29 Female 35 170 65 22.5 14.2
30 Female 37 173 75 25.1 7.0
31 Male 32 192 105 28.5 9.9
32 Male 51 183 93 27.8 39.3
33 Male 25 184 80 23.6 16.3
34 Male 55 180 85 26.2 9.2
35 Male 55 190 95 26.3 31.6
36 Male 45 177 88 28.1 7.2
37 Male 33 184 97.5 28.8 25.8
38 Male 26 171 75 25.6 3.9
39 Male 54 188 102 28.9 23.9
40 Male 32 179 76 23.7 3.4
41 Male 28 190 109 30 8.5
42 Male 31 191 94 25.8 1.8
43 Male 25 176 73 23.6 29.3
44 Male 28 191 92 25.2 35.0
45 Male 58 170 61 21.1 36.8
46 Male 46 183 90 26.9 2.3
47 Male 28 185 83 24.3 5.8
48 Male 28 189 92.5 25.9 14.7
49 Male 28 205 118 28.1 2.7
50 Male 40 183 96 28.7 12.4
51 Male 24 177 77 24.6 38.5
52 Male 29 190 84 23.3 3.8
53 Male 29 178 84 26.5 19.1
54 Male 32 192 96 26 27.9
55 Male 40 181 89 27.2 18.9
56 Male 26 190 91 25.2 13.3
57 Male 43 187 104 29.7 2.0
58 Male 29 182 86 26 20.2
59 Male 26 185 85 24.8 38.5
60 Male 36 182 80 24.2 9.2
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Table 2 
Reference intervals of hs-cTnI concentrations in random 
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Clinical application of the results of the determination 
of cTnI concentration is very oft en limited if older 
generation methods are used because of their low ana-
lytical sensitivity. Th e term “high sensitivity” refers to 
the analytical characteristics of the same method, not 
to the measurement of some other form of cardiac tro-
ponin I (15). Th ese methods must meet the two basic 
criteria: they must be able to reliably measure (values 
above the detection limit) the concentration of cTnI in 
at least 50% of a healthy population with a variation 
coeffi  cient of <10% at the 99th percentile of the upper 
limit of the reference interval, which represents great 
improvement over older methods that detect values in 
<20% of healthy population (15).
Th e restriction of the older generation method did 
not allow determination of biological variability (16), 
which has become usable by the introduction of high-
ly sensitive methods. Clinical application of the results 
of the determination of hs-cTnI has a strong infl uence 
on short-term intra-individual (CVI) and inter-indi-
vidual (CVG) variability. Values for CVI (%) are 15.2-
24.4 and for CVG (%) 70.5-124 (17,18). Despite the 
improved analytical characteristics of highly sensitive 
methods (analytical sensitivity and precision), there is 
still a problem when comparing the results of diff erent 
tests due to non-standardization of the methods. Th e 
reason for this is the lack of a commutable certifi ed ref-
erence material that would provide metrological trace-
ability (15). Despite the use of monoclonal proteins 
that have contributed to better specifi city and sensitiv-
ity, the interpretation of results should have in mind 
both posttranslational and proteolytic modifi cations 
and polymorphisms of a single nucleotide aff ecting the 
structure of the cardiac troponin I molecule and may 
aff ect its immunoreactivity in human samples (15).
CONCLUSION
Using the chemiluminescent immunochemical meth-
od on microparticles (CMIA, ARCHITECT STAT 
High Sensitive Troponin-I) on the Abbott Architect 
i1000SR (Abbott Laboratories) analytical system, we 
established 39.3 ng/L for males and 35.2 ng/L for fe-
males as a preliminary 99th percentile of the upper lim-
it of the reference interval in random urine samples 
of the selected reference persons from Croatia. Th e 
preliminary results obtained show that troponin I is 
removed from the blood via kidneys and can be deter-
mined in the urine by the CMIA, ARCHITECT STAT 
High Sensitive Troponin-I used to determine TnI in 
plasma.
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Cilj ovoga istraživanja bio je odrediti preliminarne referentne intervale visokoosjetljivog troponina l u mokraći zdravih oso-
ba. Koncentracije srčanog visokoosjetljivog troponina I u slučajnim uzorcima mokraće određene su na analitičkom sustavu 
Abbott Architecti1000SR (Abbott Laboratories) kemiluminiscentnom imunokemijskom metodom na mikročesticama (CMIA, 
ARCHITECT STAT High Sensitive Troponin-I), akreditiranom prema HR EN ISO 15189. Referentni interval izrađen je u Refer-
entnom centru Ministarstva zdravstva Republike Hrvatske za izradu referentnih vrijednosti u području opće medicinske bi-
okemije na uzorku od 30 referentnih osoba po spolu sljedećih karakteristika: nepušač, 25-65 godina, indeks tjelesne mase 
<30 kg/m2, odsutnost akutne i kronične bolesti, bez noćnog rada tijekom zadnjih 30 dana. Granica kvantiﬁ kacija određena 
je sukladno smjernicama CLSI EP17-A2 i uz zadovoljavanje kriterija za preciznost za visokoosjetljivi test (KV<10 %). Lin-
earnost metode u deklariranom području potvrđena je multikalibracijskom krivuljom. Ukupna laboratorijska preciznost 
izračunata je sukladno smjernicama CLSI EP15-A2 i iznosi 2,23 % (KV) u normalnom području i 1,45% (KV) u patološkom 
području. Proširena mjerna nesigurnost (k=2) izračunata je iz ukupne laboratorijske preciznosti i mjerne nesigurnosti kali-
bratora i iznosi ±4,5 % za normalno područje i ±2,9 % za patološko područje; 99. percentila gornje granice referentnog 
intervala izračunata je neparametarskom statističkom analizom, sukladno smjernicama CLSI C28-A3. Određena 99. per-
centila gornje granice referentnog intervala za visokoosjetljivi troponin I u mokraći iznosi 39,3 ng/L za muškarce i 35,2 ng/L 
za žene. Dobiveni preliminarni rezultati ukazuju na to da se troponin I odstranjuje iz krvi putem bubrega i da se može pou-
zdano mjeriti na analitičkom sustavu Abbott Architecti1000SR (Abbott Laboratories) kemiluminiscentnom imunokemijskom 
metodom na mikročesticama.
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